Structure Therapeutics Inc. (GPCR) Stock Analysis

Q: What is the GPCR stock price target?

Take-profit $95.82 (+165.4% upside). Prior stop was $34.71.

Q: What are the risks of investing in GPCR?

Concentration risk — Pipeline: aleniglipron; Quality below floor (1.7 < 4.0); Quality below floor (1.7 < 4.0); Momentum score 3.6/10 — below 4.5 minimum.

Q: Is GPCR overvalued or undervalued?

Structure Therapeutics Inc. trades at a P/E of N/A (forward -18.5). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about GPCR?

24 analysts cover GPCR with a consensus score of 4.3/5. Average price target: $106.

Q: What does Structure Therapeutics Inc. do?

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule GLP-1R agonists for obesity; lead candidate aleniglipron completed Phase 2b ACCESS program showing up to 11.3% placebo-adjusted weight loss at 36 weeks, with Phase 3 planned H2 2026. Pre-revenue; net loss was $141.2M in 2025 with $470.3M accumulated deficit; funded through equity with ~$191.5M remaining under ATM as of Dec 2025.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 1 days ago (May 19, 2026, 8:01 AM ET)

Healthcare · Biotechnology

$36.10+165.4% A.UpsideScore 5.3/10#67 of 157 Biotechnology

QualityF-score4 / 9FCF yield—

Stop $34.71Target $95.82(analyst − 10%)A.R:R 13.0:1

Analyst target$106.47+194.9%16 analysts

$95.82our TP

$36.10price

$106.47mean

$145

Sell if holding. Engine safety override at $36.10: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 13.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Structure Therapeutics Inc.

Latest news

Structure Therapeutics Amends And Restates Sales Agreement With Leerink Partners LLC And Cantor Fitzgerald & Co. On May — benzinga May 7, 2026 neutral
Structure Therapeutics Q1 EPS $(0.35), Inline — benzinga May 7, 2026 neutral
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101 — benzinga Apr 27, 2026 positive
Structure Therapeutics Appoints Matthew Lang COO — benzinga Apr 14, 2026 positive

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Pipeline: aleniglipron

Quality below floor (1.7 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-18.5

Mkt Cap$2.6B

EV/EBITDA-28.5

Profit Mgn0.0%

ROE-15.0%

Rev Growth—

Beta—

DividendNone

Rating analysts24

Quality Signals

Piotroski F4/9

Options Flow

P/C0.21bullish

IV75%elevated

Max Pain$30-16.9% vs spot

Concentration Risks(10-K Item 1A)

HIGHpipelinealeniglipron
10-K Item 1: 'Our most advanced product candidate to date is aleniglipron ... currently in five ongoing clinical studies for the treatment of obesity, overweight and related conditions'

Material Events(8-K, last 90d)

2026-04-15Item 5.02LOW
Matthew Lang appointed as Chief Operating Officer and General Counsel effective April 15, 2026. Previously CLO/Corporate Secretary at Metsera (2025-2026) and CBO/CLO at Lyell Immunopharma (2023-2025).
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.715%0.26

Growth5.015%0.75

Momentum3.610%0.36

Sentiment8.110%0.81

Insider Activity3.810%0.38

Peer Rank6.010%0.60

Technical Setup6.35%0.32

Risk Profile4.45%0.22

Catalyst5.35%0.27

Overall (Σ contributions)5.30

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Moat

4.0

Piotroski F

4.4

Current Ratio

5.0

No competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Ma Position

2.2

Volume

2.6

Rsi

3.0

Macd

3.5

Obv

6.6

Capitulation risk (RSI 25, below 200MA)Below 200-MA but MA still rising (+9.2%/30d) — pullback in uptrend, not confirmed weakness

GatesMomentum 3.6<4.5A.R:R 13.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

25 · Oversold

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $35.78Resistance $48.62

Price Targets

$35

$96

A.Upside+165.4%

A.R:R13.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.7 < 4.0)

! Momentum score 3.6/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is GPCR stock a buy right now?

Sell if holding. Engine safety override at $36.10: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 13.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $34.71. Score 5.3/10, moderate confidence.

What is the GPCR stock price target?

Take-profit target: $95.82 (+165.4% upside). Prior stop was $34.71. Stop-loss: $34.71.

What are the risks of investing in GPCR?

Concentration risk — Pipeline: aleniglipron; Quality below floor (1.7 < 4.0).

Is GPCR overvalued or undervalued?

Structure Therapeutics Inc. trades at a P/E of N/A (forward -18.5). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about GPCR?

24 analysts cover GPCR with a consensus score of 4.3/5. Average price target: $106.

What does Structure Therapeutics Inc. do?Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule GLP-1R agonists for...

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule GLP-1R agonists for obesity; lead candidate aleniglipron completed Phase 2b ACCESS program showing up to 11.3% placebo-adjusted weight loss at 36 weeks, with Phase 3 planned H2 2026. Pre-revenue; net loss was $141.2M in 2025 with $470.3M accumulated deficit; funded through equity with ~$191.5M remaining under ATM as of Dec 2025.